Pharmaceutical Preparations · DE · CIK 1761918
Erasca develops therapies for RAS/MAPK pathway-driven cancers by targeting key signaling nodes and escape routes
Comparable business profile · signals at a glance
In the 90 days to Mar 4, 2026: 2 sold $972K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Morris ShannonChief Medical Officer | Sell | 20,000 | $15.04 | $301K |
| Jan 7, 2026 | Garner EbunGeneral Counsel & Corp. Sec. | Sell | 120,000 | $5.59 | $671K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.